View item

US National Institutes of Health – The Role of Mobile Genetic Elements in Cancer (R21 Clinical Trials Not Allowed) – PAR-16-226
Sponsor: US National Institutes of Health 		Closing Date: 16-Oct-2018
The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood. In an effort to address this knowledge gap, this FOA invites research proposals that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports high risk exploratory and/or developmental research applications that propose to investigate novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially move the field forward. An R21 application need not have extensive background material or preliminary information.

Eligibility
• Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
• Applications from Foreign Organizations: Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Funding
• Direct costs are limited to USD $275,000 over a two-year project period, with no more than USD $200,000 in direct costs allowed in any single year.
• The maximum project period is 2 years.

Please see the Funding Opportunity Announcement for further information. Applications may be prepared and submitted via the NIH ASSIST system or Grants.gov. For complete instructions, you must refer to both the NIH Application Guide and the Funding Opportunity Announcement (FOA), noting that instructions in the FOA take precedence over the Application Guide.

Key Dates
Letter of Intent (non-mandatory) due to NIH: Not Applicable
Applications due to UQR&I: 2 October 2018
Applications close with NIH: 16 October 2018, 5:00pm local time of applicant organisation
Future application closing dates: Standard dates apply until expiry
Expiration date of FOA: 8 September 2019

Ahead of internal review, ensure all online components on ASSIST or Grants.gov are complete. To initiate review, email your completed Funding Application Coversheet to internationalgrants@research.uq.edu.au. Interested applicants are strongly encouraged to make contact with the UQR&I international team (via internationalgrants@research.uq.edu.au) well in advance of the UQR&I internal deadline to discuss their application.
Website: https://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html

Return